Research
Jefferies Initiates Kailera Therapeutics at Buy With $48 Price Target
$KLRA
$KLRA
7 stories mentioning KLRAUpdated 42d ago
Every FINWIRES story that references KLRA, newest first.
Research
TD Cowen Initiates Kailera Therapeutics at Buy With $57 Price Target
$KLRA
Research
Leerink Initiates Kailera Therapeutics at Outperform With $36 Price Target
$KLRA
Research
Evercore ISI Kailera Therapeutics Initiates at Outperform
$KLRA
Research
William Blair Initiates Kailera Therapeutics at Outperform
$KLRA
Insider Trading
Kailera Therapeutics Insider Bought Shares Worth $134,375,008, According to a Recent SEC Filing
Andrew T. Kaplan, 10% Owner, Director, on April 16, 2026, executed a purchase for 8,398,438 shares in Kailera Therapeutics (KLRA) for $134,375,008. Following the Form 4 filing with the SEC, Kaplan has control over a total of 26,255,581 common shares of the company, with 26,255,581 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2096997/000119312526164388/xslF345X05/ownership.xml
$KLRA
Insider Trading
Kailera Therapeutics Insider Bought Shares Worth $25,000,000, According to a Recent SEC Filing
Adam Koppel, 10% Owner, Director, on April 16, 2026, executed a purchase for 1,562,500 shares in Kailera Therapeutics (KLRA) for $25,000,000. Following the Form 4 filing with the SEC, Koppel has control over a total of 22,583,268 common shares of the company, with 22,583,268 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2096997/000119312526164407/xslF345X05/ownership.xml
$KLRA
